

SARS-COV-2 NEUTRALIZING ANTIBODY EFFECTIVE AGAINST ALL VARIANTS

Adams, Lucas, Diamond, Michael, Fremont, Daved, VanBlargan, Laura

Poranki, Deepika

T-019791

Disease indication - SARS-CoV-2 infection (COVID-19)

Drug format - Chimeric monoclonal antibody

Drug class – Best-in-class

Research stage and Preliminary data – The inventors have developed and characterized this antibody, creating a chimeric version with a human IgG backbone. The antibody has been extensively tested in hACE2 transgenic mice. The researchers have also performed initial proof of concept experiments against all common SARS-CoV-2 variants (including the South Africa, UK, Brazil, and California variants) *in vitro* to show similar levels of efficacy.





Target - SARS-CoV-2 spike protein

Background – Mass vaccination is proving to be an effective strategy in combatting the spread of COVID-19. However, the emergence of new variants of SARS-CoV-2 remains a concern, particularly when the new variants show decreased susceptibility to vaccine-generated immune response due to mutations in the spike protein. Therapeutics targeted at conserved regions of the spike protein are ideally suited for use in all variants.

Mode of action – This antibody binds the viral spike protein at a highly-conserved epitope, neutralizing the virus by blocking entry at attachment and post-attachment steps.

Competitive edge – While other neutralizing antibodies for SARS-CoV-2 have been developed, they often show reduced efficacy on some variants due to mutation of the spike protein. This antibody's epitope is highly conserved across all common variants of SARS-CoV-2, providing effective treatment for all variants.

Publication – VanBlargan LA, Adams LJ, Liu Z, Chen RE, Gilchuk P, ... Diamond MS. (2021). <u>A potently neutralizing anti-</u> <u>SARS-CoV-2 antibody inhibits variants of concern by binding a highly conserved epitope</u>. *bioRxiv*.



Patent status - Pending

Web Links – Diamond Profile & Lab; Fremont Profile & Lab